Linear DNA amplicons as a novel cancer vaccine strategy.
Autor: | Conforti A; Takis, Via Castel Romano 100, 00128, Rome, Italy. conforti@evvivax.com.; Evvivax, Via Castel Romano 100, 00128, Rome, Italy. conforti@evvivax.com., Salvatori E; Takis, Via Castel Romano 100, 00128, Rome, Italy., Lione L; Takis, Via Castel Romano 100, 00128, Rome, Italy., Compagnone M; Neomatrix, Via Castel Romano 100, 00128, Rome, Italy., Pinto E; Takis, Via Castel Romano 100, 00128, Rome, Italy., Shorrock C; Applied DNA Sciences, 50 Health Sciences Drive, Stony Brook, NY, 11790, USA., Hayward JA; Applied DNA Sciences, 50 Health Sciences Drive, Stony Brook, NY, 11790, USA., Sun Y; Applied DNA Sciences, 50 Health Sciences Drive, Stony Brook, NY, 11790, USA., Liang BM; Applied DNA Sciences, 50 Health Sciences Drive, Stony Brook, NY, 11790, USA., Palombo F; Takis, Via Castel Romano 100, 00128, Rome, Italy. palombo@neomatrixbiotech.com.; Neomatrix, Via Castel Romano 100, 00128, Rome, Italy. palombo@neomatrixbiotech.com., Viscount B; Applied DNA Sciences, 50 Health Sciences Drive, Stony Brook, NY, 11790, USA. brian.viscount@adnas.com., Aurisicchio L; Takis, Via Castel Romano 100, 00128, Rome, Italy. aurisicchio@evvivax.com.; Evvivax, Via Castel Romano 100, 00128, Rome, Italy. aurisicchio@evvivax.com.; Neomatrix, Via Castel Romano 100, 00128, Rome, Italy. aurisicchio@evvivax.com. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2022 Jun 06; Vol. 41 (1), pp. 195. Date of Electronic Publication: 2022 Jun 06. |
DOI: | 10.1186/s13046-022-02402-5 |
Abstrakt: | Background: DNA-based vaccines represent a simple, safe and promising strategy for harnessing the immune system to fight infectious diseases as well as various forms of cancer and thus are considered an important tool in the cancer immunotherapy toolbox. Nonetheless, the manufacture of plasmid DNA vaccines has several drawbacks, including long lead times and the need to remove impurities from bacterial cultures. Here we report the development of polymerase chain reaction (PCR)-produced amplicon expression vectors as DNA vaccines and their in vivo application to elicit antigen-specific immune responses in animal cancer models. Methods: Plasmid DNA and amplicon expression was assessed both in vitro, by Hela cells transfection, and in vivo, by evaluating luciferase expression in wild-type mice through optical imaging. Immunogenicity induced by DNA amplicons was assessed by vaccinating wild-type mice against a tumor-associated antigen, whereas the antitumoral effect of DNA amplicons was evaluated in a murine cancer model in combination with immune-checkpoint inhibitors (ICIs). Results: Amplicons encoding tumor-associated-antigens, such as telomerase reverse transcriptase or neoantigens expressed by murine tumor cell lines, were able to elicit antigen-specific immune responses and proved to significantly impact tumor growth when administered in combination with ICIs. Conclusions: These results strongly support the further exploration of the use of PCR-based amplicons as an innovative immunotherapeutic approach to cancer treatment. (© 2022. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |